Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Sales | 371,206 | 1,198 | 914,963 | 719 | 289,590 |
Gross Profit | 371,206 | 1,198 | 914,963 | 719 | 289,590 |
Operating Expenses | 593,744 | 674,359 | 541,435 | 355,154 | 242,850 |
Operating Income | -222,538 | -673,161 | 373,528 | -354,435 | 46,740 |
Other Income | 71,816 | 22,661 | 6,003 | 6,379 | 20,566 |
Pre-tax Income | -150,722 | -650,500 | 379,531 | -348,056 | 67,306 |
Income Tax | 2,888 | -325 | 1,870 | 809 | 448 |
Net Income Continuous | -153,610 | -650,175 | 377,661 | -348,865 | 66,858 |
Net Income | $-153,610 | $-650,175 | $377,661 | $-348,865 | $66,858 |
EPS Basic Total Ops | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 |
EPS Basic Continuous Ops | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 |
EPS Diluted Total Ops | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
EPS Diluted Continuous Ops | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
EPS Diluted Before Non-Recurring Items | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
EBITDA(a) | $-202,701 | $-648,989 | $391,481 | $-343,394 | $51,465 |